Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer

The goal of this clinical trial is to see the safety and efficacy of pembrolizumab and lenvatinib in patients with anal squamous cell cancer that cannot be removed through surgery or is spread to other organs. Eligible participants should have also received some form of standard therapy previously for their advanced cancer. Participants will be required to come for a clinic visit and infusion of pembrolizumab. Lenvatinib will be taken by mouth at home based on direction provided by physicians and research team.

NCT Number	NCT07680088
Lead Sponsor	University of Texas Southwestern Medical Center Collaborators: Merck Sharp & Dohme LLC
Conditions	Anal Squamous Cell Carcinoma
Enrollment	17 participants
Start Date	2026-09-30
Primary Completion	2028-09-30 (estimated)
Study Completion	2030-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-02